KLRG1 and neoplasm: Importantly, in several mouse tumor models, it was found that KLRG1 checkpoint blockade resulted in heightened anti-tumor immunity and better outcomes, while KLRG1/PD-1 combination therapy resulted in reduced primary tumor growth as well as metastasis development (55, 57).